Skip to content
Cibinqo(abrocitinib)
Cibinqo (abrocitinib) is a small molecule pharmaceutical. Abrocitinib was first approved as Cibinqo on 2021-12-09. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis. It is known to target tyrosine-protein kinase JAK1 and tyrosine-protein kinase JAK2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Cibinqo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Abrocitinib
Tradename
Company
Number
Date
Products
CIBINQOMylanN-213871 RX2022-01-14
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cibinqoNew Drug Application2023-02-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atopic dermatitisEFO_0000274D003876L20
Agency Specific
FDA
EMA
Expiration
Code
ABROCITINIB, CIBINQO, PFIZER
2027-01-14NCE
2026-02-09NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Abrocitinib, Cibinqo, Pfizer
90350742034-02-19DS, DP
95454052034-02-19DS, DP
95499292034-02-19U-3195
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AH: Agents for dermatitis, excluding corticosteroids
— D11AH08: Abrocitinib
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L201281719
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EczemaD004485HP_0000964L30.9——2—13
Skin diseasesD012871L00-L99—12——3
Immune system diseasesD007154D89.9——2——2
Inborn genetic diseasesD030342EFO_0000508——2——2
DermatitisD003872HP_0011123L30.9——2——2
Genetic skin diseasesD012873——2——2
Eczematous skin diseasesD017443——2——2
HypersensitivityD006967EFO_0003785T78.40——2——2
Immediate hypersensitivityD006969——2——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L40—1——12
PruritusD011537HP_0000989L29—1———1
PrurigoD011536L28.2—1———1
Type 1 diabetes mellitusD003922EFO_0001359E10—1———1
SarcoidosisD012507EFO_0000690D80-D89—1———1
Granuloma annulareD016460L92.0—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—12————12
Renal insufficiencyD051437HP_0000083N191————1
Hepatic insufficiencyD0485501————1
Food hypersensitivityD005512EFO_10018901————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameABROCITINIB
INNabrocitinib
Description
Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.
Classification
Small molecule
Drug classtyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Identifiers
PDB6BBU
CAS-ID1622902-68-4
RxCUI—
ChEMBL IDCHEMBL3655081
ChEBI ID—
PubChem CID78323835
DrugBankDB14973
UNII ID73SM5SF3OR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
JAK1
JAK1
JAK2
JAK2
Organism
Homo sapiens
Gene name
JAK1
Gene synonyms
JAK1A, JAK1B
NCBI Gene ID
3716
Protein name
tyrosine-protein kinase JAK1
Protein synonyms
JAK-1, Janus kinase 1
Uniprot ID
Q9UD26
Mouse ortholog
Jak1 (16451)
tyrosine-protein kinase JAK1 (P52332)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 358 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cibinqo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3 adverse events reported
View more details